WA-EKATA
7.4.2021 15:02:11 CEST | Business Wire | Press release
Ekata , the leader in global digital identity data, today announced its Merchant Onboarding solution to help payment service providers (PSPs), B2B lenders and marketplaces onboard the growing number of micro-merchants and sole proprietors across the globe faster and with more confidence. The lack of commercial track record for these new small businesses makes it difficult for PSPs and lenders to quickly and confidently approve them using traditional methods of risk assessment. Ekata set out to help customers enhance their existing models with risk indicators that show fraud likelihood based on a mix of comprehensive customer data tests and best-practice considerations. By providing unique data that cross-checks the connection between businesses and the individuals behind them, Ekata’s new merchant onboarding solution enables organizations to confidently assess risk at scale, automate onboarding workflows, and reduce time spent in manual review.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005320/en/
The global pandemic accelerated an existing trend of individuals establishing their own small businesses. In the U.S. alone there are 30 million small merchants and an additional 40 million individuals who became independent contractors in 2020. Similarly, Europe has 25.1 million small businesses and a growing 33 million sole proprietors . On the tailwinds of this trend, Covid-19 added some additional unexpected fuel: in October 2020, the U.S. Census Bureau published the business-formation statistics for the third quarter of 2020. Third-quarter 2020 business applications rose by 77.4% from June to September .
With this massive growth comes an increasing demand for quick and effective onboarding of these merchants by PSPs and lending institutions. Companies like Stripe, Square, PayPal and others have set a new standard by cutting onboarding times from 2-3 days to just minutes, often threatening the business viability of other PSPs whose processes and risk assessments can’t keep up with their pace. In this intensely competitive market, Ekata’s solution helps PSPs and lenders respond to the increasing expectations for speedier onboarding.
“Merchants today have plenty of options and will quickly turn to another payment service provider if an organization adds too much friction at onboarding or takes too long on approvals ,” says Beth Shulkin, Ekata’s VP of Global Marketing. “This is much more than a customer experience issue for PSPs and lenders; losing the lifetime value of a merchant has real bottom-line impact .”
Ekata’s holistic solution is designed to solve both sides of the flow: automating the onboarding process via APIs and enabling more efficient manual reviews with a SaaS solution. Our API integrates easily with existing rules or machine learning-based risk models, and our SaaS product quickly surfaces correlations between key individual and business identity attributes on easy-to-read dashboards.
Key benefits of the Merchant Onboarding solution include:
- Onboard micro-merchants and sole proprietor businesses with higher confidence: With individual, business, and unique cross-linked signals, Ekata customers can build trusted risk profiles for micro-merchants and sole proprietors that lack the typical track record - verifying information and approving or rejecting applications with confidence.
- Quickly route good customers for automated underwriting: Businesses can shift low-risk merchant applications away from high friction onboarding steps such as supplemental document collection and manual review, towards automated approval, which gets these customers onboard and generating revenue as quickly as possible. They can then focus on high-risk customers that need additional documentation or manual review.
- Reduce time spent in manual review: Businesses can quickly view a key set of individual and business data, reducing the time needed to research data across multiple sources and helping the reviewer make a faster, more efficient, and more accurate decision.
For additional information on Ekata’s Merchant Onboarding API, visit here . To learn more about Ekata’s Merchant Review, visit here .
About Ekata
Ekata provides global identity verification via APIs and a SaaS solution to provide businesses worldwide the ability to link any digital transaction to the human behind it. The Ekata product suite is powered by the Ekata Identity Engine, our proprietary, intellectual property, that uses unique datasets from the Ekata Identity Graph and the Ekata Identity Network that provides identity verification data with consistent results across the globe, in industry-leading response times, to enable businesses around the world like AliPay, Microsoft, Stripe, and Airbnb to fight fraud, reduce false declines, and make accurate risk decisions about their customers faster than the blink of an eye.
Ekata is a trademark of Ekata, Inc. All other trade names, trademarks and registered trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
